학술논문
Safety and effectiveness of SARS-CoV-2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire-based, cross-sectional study.
Document Type
Academic Journal
Author
Tanifuji A; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.; Ohfuji S; Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.; Matsumoto K; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.; Abe M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.; Komori A; Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki, Japan.; Takahashi A; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.; Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka, Japan.; Sato K; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan.; Joshita S; Division of Hepatology and Gastroenterology, Department of Medicine, Shinshu University School of Medicine, Nagano, Japan.; Umemura T; Division of Hepatology and Gastroenterology, Department of Medicine, Shinshu University School of Medicine, Nagano, Japan.; Ueno M; Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Okayama, Japan.; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Nakayama N; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.; Kakisaka K; Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.; Arinaga-Hino T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.; Ito K; Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.; Kanai S; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Miura R; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.; Arizumi T; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.; Asaoka Y; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.; Ito T; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi, Japan.; Shimizu T; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.; Yoshida H; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.; Ohta M; Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Oita, Japan.; Mizuno S; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.; Isayama H; Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.; Morimoto Y; Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Okayama, Japan.; Mochida S; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.; Ohira H; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.; Tanaka A; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Source
Publisher: Blackwell Publishing Country of Publication: Netherlands NLM ID: 9711801 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1386-6346 (Print) Linking ISSN: 13866346 NLM ISO Abbreviation: Hepatol Res Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1386-6346
Abstract
Aim: There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire-based, cross-sectional study to determine the safety and effectiveness of the SARS-CoV-2 vaccines in Japanese patients with intractable hepatobiliary disease.
Methods: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd-Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post-vaccination adverse effects, and SARS-CoV-2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre- and post-vaccination were collected.
Results: The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH- primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd-Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post-vaccination adverse effects were comparable to those observed in the general population. Post-vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH-like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS-CoV-2, and only one patient was infected 6 months after the second vaccination.
Conclusion: SARS-CoV-2 vaccines demonstrated satisfactory safety and effectiveness in Japanese patients with intractable hepatobiliary diseases.
(© 2024 Japan Society of Hepatology.)
Methods: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd-Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post-vaccination adverse effects, and SARS-CoV-2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre- and post-vaccination were collected.
Results: The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH- primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd-Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post-vaccination adverse effects were comparable to those observed in the general population. Post-vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH-like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS-CoV-2, and only one patient was infected 6 months after the second vaccination.
Conclusion: SARS-CoV-2 vaccines demonstrated satisfactory safety and effectiveness in Japanese patients with intractable hepatobiliary diseases.
(© 2024 Japan Society of Hepatology.)